Free Newsletter
| Get the pharma industry's daily monitor, with a special focus on pharmaceutical company news and the market development of FDA approved products. Sign up for free today! |
Teva earmarks $1B for India
Here's more evidence that the developing world is hot, hot, hot. Teva Pharmaceutical Industries plans to invest a whopping $1 billion in India. The generics giant will spend between a quarter and a third of that on new manufacturing plants. The rest will go into acquisitions.
Teva recently bought 100 acres in Madhya Pradesh for new active pharmaceutical ingredient facilities. And banking sources told the Business Standard that Teva has been chasing major acquisitions on the subcontinent for three years. Possible targets: Indian drug makers Cipla, Aurobindo, Matrix, and Orchid.
"Teva considers India an interesting geographical region," a company spokeswoman told the local newspaper, "and is looking to broaden its activities in the country." Indeed.
- get the article in the Business Standard
- read this Pharmalot item
Related Articles:
Biotechnology will expand its global reach. Report
Big Pharma blunders in emerging world. Report
Research (and marketing) heads to Asia. Report
Bangalore Bio: India's biotech future is bright. Report
Comments
Post new comment
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness


